Genmab (GMAB) is maintaining its 2025 financial guidance published on February 12, 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Executes Share Buy-back Transactions in Early May 2025
- Genmab to Submit sBLA for Epcoritamab Combination in Follicular Lymphoma
- Genmab Continues Share Buy-back Program in April 2025
- Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC
- Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating